New commentaries suggest that the real-world impact of the 2025 ACC/AHA/HRS/ISACHD/SCAI guideline for adults with congenital heart disease (ACHD) will depend on how well it is adapted to overlapping domains such as valvular heart disease (VHD) and to low-resource health systems.